A daunorubicin β-galactoside prodrug for use in conjunction with gene- directed enzyme prodrug therapy

Tetrahedron Letters

Volumn 41, Issue 25, 2000, Pages 4871-4874

  Ghosh, Ajit K ^a   Khan, Saeed ^a   Marini, Frank ^a   Nelson, J Arly ^a   Farquhar, David ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracycline; Daunomycin; Gene therapy; Prodrug; Galactosidase

Indexed keywords

BENZYL ALCOHOL DERIVATIVE; BETA GALACTOSIDASE; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; PRODRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DEGRADATION; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

EID: 0034686261     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(00)00742-5     Document Type: Article

References (20)

1. Myers, C. E. Cancer Chemotherapy & Biological Response Modifiers 1992, 13, 45-52.
2. Mott, M. G. Anal. N.Y. Acad. Sci. 1997, 824, 221-228.
3. Kroger, N.; Achterrath, W.; Hegewisch-Becker, S.; Mross, K.; Zander, A. R. Cancer Treatment Reviews 1999, 25, 279-291.
4. Farquhar, D.; Ghosh, A. K.; Bakina, E.; Marini, F. Proc. Amer. Assoc. Cancer Res. 1997, 38, 613 (4121).
5. Marini, F.; Ghosh, A. K.; Bakina, E.; Nelson, J. A.; Farquhar, D. Proc. Amer. Assoc. Cancer Res. 1997, 38, 342 (2294).
6. Ghosh, A. K.; Khan, S. R.; Farquhar, D. Chem. Commun. 1999, 24, 2527-2529.
7. Bakina, E.; Farquhar, D. Anti-Cancer Drug Des. 1999, 14 (6), in press.
8. Bakina, E.; Wu, Z.; Rosenblum, M. Proc. Amer. Assoc. Cancer Res. 1997, 38, 432 (2895).
9. Farquhar, D.; Ghosh, A. K.; Nelson, J. A. Proc. Amer. Assoc. Cancer Res. 1998, 39, 219 (1494).
10. Bakina, E.; Wu, Z.; Rosenblum, M.; Farquhar D. J. Med. Chem. 1997, 40, 4013-4018.
11. Ghosh, A. K.; Farquhar, D. Tetrahedron Lett. 1997, 38, 8795-8798.
12. Bagshawe, K. D. Br. J. Cancer 1989, 60, 275-281.
13. Gutierrez, A. A.; Lemoine, N. R.; Sikora, K. Lancet 1992, 339, 715-721.
14. Macgregor, G. R.; Nolan, G. P.; Fiering, S.; Roeder, M.; Herzenberg, L. A. Methods Mol. Biol. 1991, 7, 217-235.
15. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. J. Med. Chem. 1981, 24, 479-480.
16. Andrianomenjanahary, S.; Dong, X.; Florent, J. C.; Gaudel, G.; Gesson, J. P.; Jacquesy, J. C.; Koch, M.; Michel, S.; Mondon, M.; Monneret, C.; Petit, P.; Renoux, B.; Tillequin, F. J. Bioorg. Med. Chem. Lett. 1992, 2, 1093-1096.
17. Bosslet, K.; Czech, J.; Hoffmann, D. Cancer Res. 1994, 54, 2151-2159.
18. Bollenback, G. N.; Long, J. W.; Benjamin, D. G.; Lindquist, J. A. J. Am. Chem. Soc. 1955, 77, 3310.
19. +.
20. 3CN (3:2) at a flow rate of 1.0 ml per min. Prodrug 1 and the enzyme reaction products were monitored by a variable wavelength UV detector set at 254 nm with 0.01 AUFS sensitivity (Waters 484 model) and quantitated electronically as a function of time using a NEC Pinwriter P6200 integrator. The half-lives were determined by non-linear regression analysis. β-Galactosidase was used as received from Sigma Company (catalog number G-2513).